Shots:

• AstraZeneca to receive $35M upfront with future sales-contingent payments of up to $6M and it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period
• The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its portfolio of mature medicines. In earlier 2019- AstraZeneca divested the rights of these atypical antipsychotic therapies to Cheplapharm in EU (Ex- UK) and Russia
• Seroquel & Seroquel XR are anti-psychotic therapies with antidepressant properties indicated to treat schizophrenia and bipolar disorder and has generated $36M & $79M revenue in 2018 in the US and Canada respectively

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: Delaware online